OncLive poll shows oncogene-driven NSCLC as top focus for lung cancer abstracts at ASCO 2026

OncLive surveyed its LinkedIn and X followers to learn which lung cancer topics will draw the most attention at the 2026 ASCO Annual Meeting in Chicago. The poll asked participants to select the area they expect to focus on, ranging from oncogene-driven non-small cell lung cancer (NSCLC) to adjuvant therapy and small cell lung cancer.

Among 30 LinkedIn respondents, 60% chose oncogene-driven NSCLC, while adjuvant therapy, frontline squamous NSCLC and extensive-stage SCLC each received 13%. On X, six respondents voted, with 50% selecting oncogene-driven NSCLC, 33% picking frontline squamous NSCLC and 17% opting for extensive-stage SCLC.

The results suggest the lung cancer community anticipates that data on oncogene-driven NSCLC will dominate discussions at ASCO, though interest remains in adjuvant strategies, squamous disease and extensive-stage small cell lung cancer as well.